# A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct07321678` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07321678](<https://clinicaltrials.gov/study/NCT07321678>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07321678

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT07321678. Randomized; quadruple masking; primary purpose treatment. Start 2026-01-22 (actual); primary completion 2026-08-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT07321678, source copy `cardio:ctgov-nct07321678-2026-10-30`, retrieved 2026-10-31)
- Started: 2026-01-22 (actual) (ClinicalTrials.gov record NCT07321678, source copy `cardio:ctgov-nct07321678-2026-10-30`, retrieved 2026-10-31)
- Primary completion: 2026-08-10 (actual) (ClinicalTrials.gov record NCT07321678, source copy `cardio:ctgov-nct07321678-2026-10-30`, retrieved 2026-10-31)
- Completion: 2026-08-10 (actual) (ClinicalTrials.gov record NCT07321678, source copy `cardio:ctgov-nct07321678-2026-10-30`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT07321678, source copy `cardio:ctgov-nct07321678-2026-10-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07321678-2026-10-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus
- Condition: T2DM (Type 2 Diabetes Mellitus)
- Intervention (Drug): ASC30 tablets
- Intervention (Drug): Placebo
- Lead sponsor: Ascletis Pharma (China) Co., Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 42a1ac6f22b9f8399d943277ce27c7ad612697154ca5412fd53c08b3f0b86aee
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
